Document:

EX-10.23

 Exhibit 10.23 
 Confidential Materials omitted and filed separately with the Securities and Exchange Commission. 
 Triple asterisks denote omissions. 
 Amendment No. 1 to
Agreement 
 (“Amendment No. 1”) 

Date: August 9, 2012 
  

			
	Name of Original Agreement:	  	Research Collaboration and License Agreement (the “Agreement”)
		
	Effective Date of Original Agreement:	  	October 13, 2010 (“Effective Date”)
		
	Parties:	  	Pfizer Inc. (“Pfizer”) and MacroGenics, Inc. (“MacroGenics”)

 Capitalized terms used but not defined herein shall have the meanings ascribed to such terms in the Agreement.

 WHEREAS, the parties hereto desire to amend, among other things, certain terms of the Agreement including increasing, by 1 month, the time
allowed for Target Substitution. 
 NOW, THEREFORE, in order to accommodate the changes, the parties have agreed as follows: 

1. Sections 2.1.3, 2.1.4 2.1.5, and 9.4 of the Agreement are revised to read, in their entirety, as follows: 

2.13 Substitution of Targets. Pfizer may request that additional Targets be substituted on a one-for-one basis for the Second
Research Project Target or any Reserved Target in accordance with this Section 02.1.3. 
  

	 	a.	At any time within *** following the Effective Date, Pfizer may substitute, without limitation on the number of substitutions and on a one-for-one basis, for the Second
Research Project Target and the Reserved Targets. 

  

	 	b.	At any time beginning *** after the Effective Date and continuing until the earlier of (i) *** following the Effective Date, and (ii) ***, Pfizer may request
that additional Targets be substituted on a one-for-one basis for any existing Reserved Targets. 

  

	 	c.	 Subject to (d), MacroGenics will allow such substitutions set forth in (a) and (b), except that it may decline a proposed Target substitution
based on (i) *** *** shall not decline a proposed Target substitution based on clause (i) or (ii) unless such agreement or term sheet with such Third Party precludes or limits MacroGenics’ ability to perform research
regarding such Target or to grant Pfizer the rights to be granted by MacroGenics to Pfizer under this Agreement. In addition to the foregoing conditions upon which MacroGenics may decline a proposed Target substitution, MacroGenics may, in its sole
discretion, veto up to *** proposed Target substitutions proposed during the period specified in Section 2.1.3(b) by Pfizer for any reason and *** proposed Target substitution proposed

	 	
during the period specified in Section 2.1.3(a) by Pfizer for any reason. Any Targets substituted for an existing Reserved Target will then be deemed to be included within the definition of
Reserved Targets. 

  

	 	d.	Notwithstanding any other provision of this Agreement, during the *** following the Effective Date, MacroGenics at its sole discretion shall be entitled to decline any
substitutions under 2.1.3(b) for any reason in addition to any Target substitutions declined under 2.1.3(c). 

 2.14 Elevation
of Reserved Targets. At any time in the *** following the Effective Date, Pfizer may submit a written notice to MacroGenics that up to two Reserved Targets will be substituted for any then-designated Research Project Target on a
one-for-one basis. Any such Reserved Target substituted for an existing Research Project Target will then be deemed to be included within the definition of Research Project Target. 
 2.15 Former Reserved Targets. Any Reserved Targets shall cease to be a Reserved Target for all purposes under this Agreement (including under Section 4.5) upon the earlier of
(a) replacement of such Reserved Target with a new Target in accordance with Section 2.1.3(b), or (b) *** following the Effective Date. 
 9.4 Termination by Pfizer without Cause. Pfizer shall have the right to terminate the Agreement at any time for any or no reason, on a Research Project Target-by-Research Project Target basis, by
providing *** advance written notice of such termination to MacroGenics; provided that, during the first *** following the Effective Date, Pfizer will retain at least one Research Project Target under the Research Program. Commencing
*** following the Effective Date, Pfizer shall have the right, exercisable upon *** prior written notice to MacroGenics, to terminate this Agreement at any time for any or no reason either (a) in its entirety or (b) on a
Research Project Target-by-Research Project Target basis. 
 2. Except as expressly amended hereby, the Agreement shall remain unmodified and in
full force and effect. The execution, delivery and effectiveness of this Amendment No. 1 shall not, except as expressly provided herein, operate as a waiver of any right, power or remedy of the parties to the Agreement, nor constitute a waiver
of any provision of the Agreement. 
 3. This Amendment No. 1 may be executed in any number of counterparts, each of which shall be an
original instrument and all of which, when taken together, shall constitute one and the same agreement. 
 SIGNATURES IMMEDIATELY
FOLLOWING ON NEXT PAGE 

  
 2 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission. 

 IN WITNESS WHEREOF, the duly authorized representatives of Pfizer and SCRX have executed this Amendment
No. 1 as of the date first above written. 
  

									
	MacroGenics, Inc.	  		 	Pfizer Inc.
					
	By	  	 /s/ Scott Koenig
	  		 	By	 	 /s/ Steven Adams

	Print Name:	  	 Scott Koenig
	  		 	Print Name:	 	 Steven Adams

	Title:	  	 CEO
	  		 	Title:	 	 SR Director Operations Oncology Research

		  	(Duly authorized)	  		 		 	(Duly authorized)

  

  
 3 

 *** = Portions of this exhibit have been omitted pursuant to a request for confidential
treatment. An unredacted 
 version of this exhibit has been filed separately with the Commission.f8k081513ex10i_hoteloutsourc.htm

Exhibit 10.1

 

	
CANCELLATION MEMO 

 

DATED AS OF AUGUST 15, 2013

 

	BY AND BETWEEN:	HOMI INDUSTRIES LTD, an Israeli company, #512805193, whose address for the purposes of this Memo shall be Merkazim A Building, 1 Aba Eben Street, 3rd Floor, Herzliya Pituach Herzliya Pituach 46725, Israel; Fax: +972-9-9728626, e-mail: jackronnel@my-homi.com, with a mandatory copy to Reif & Reif Law Offices, e-mail: Mail@ReifLaw.com (“HOMI”);
	 	 
	AND:	
BAHRY BUSINESS & FINANCE (1994) LTD, an Israeli company, #511939670, whose address for the purposes of this Memo shall be c/o Avraham Bahry, 1 Gan Hashikmim St., Savion 5690500 (“Lender”);

	 	 
	WHEREAS:	
HOMI and Lender entered into a Loan Agreement, dated as of September 1, 2012 (the “Loan Agreement”), whereby Lender loaned to HOMI the amount of $200,901.- (two hundred thousand nine hundred and one US Dollars) (the “Loan”), to be repaid on the basis of a computation of revenues received by HOMI’s affiliate, HOMI UK Ltd (the “Affiliate”), from a turnkey computerized mini-bar system operated by the Affiliate at the Hilton Olympia Hotel in London (the “Minibar System”); and

	 	 
	WHEREAS:	
the outstanding balance of the Loan, will, after HOMI pays to Lender the repayments due in respect of June 2013 and July 2013, be $165,029.-  (one hundred and sixty five thousand and twenty-nine US Dollars) (the “Outstanding Loan Balance”);

	 	 
	WHEREAS:	HOMI and Lender entered into a Deed of Pledge, dated as of September 1, 2012 (the “Existing Deed of  Pledge”), pursuant to  which HOMI created a  fixed charge, in Lender’s favour, over the Minibar System, which was registered as HOMI’s Charge No. 8 with Israel’s Registrar of Companies (the “Existing Charge”);
	 	 
	WHEREAS:	Lender  has  notified  HOMI  that  it  has  assigned  all  of  its  rights  under  the  Loan Agreement, to Alon Mordoch (90%) and Ilan Bahry (10%) (collectively, the “Assignees”) and has requested that HOMI create and register a fixed charge (the “New Charge”) over the Minibar System, in favour of the Assignees, in an amount equal to the Outstanding Loan Balance, which charge will come in place of the Existing Charge, pursuant to a new deed of pledge, between HOMI and the Assignees, in substantially the same form as the Existing Deed of Pledge (the “New Deed of Pledge”);

 

THEREFORE, THE PARTIES HAVE MADE CONDITION AND AGREED AS FOLLOWS:

 

	1. 	The Existing Deed of Pledge; The Existing Charge
	 	 
	With a view to facilitating the creation and registration of the New Charge, pursuant to the New Deed of Pledge:
	 	 
	1.1    	the Existing Deed of Pledge is hereby terminated with immediate effect, and neither Party has or shall have any claim against the other in respect of the Existing Deed of Pledge and/or said termination thereof;
	 	 
	1.2    	Lender will, concurrent with the execution of this Memo, execute and deliver to HOMI a letter from Lender  to  Israel’s  Registrar of  Companies, requesting the  immediate  cancellation  of  the  Existing Charge, and HOMI will file this letter with the Registrar of Companies in order to cancel the Existing Charge.
	 	 
	2.	The New Deed of Pledge; The New Charge
	 	 
	2.1   	Lender will, concurrent with the execution of this Memo, deliver to HOMI the New Deed of Pledge, as prepared by HOMI, duly signed by the Assignees in three original counterparts. HOMI will then countersign the New Deed of Pledge, in order to create the New Charge, and will file it with the Registrar of Companies, together with a duly executed Form 10, in order to register the New Charge.

 

  

  

  

 

	
Cancellation Memo

HOMI Industries – Bahry Business 

	 

 

	2.2    	HOMI will notify Lender upon the Registrar of Companies’ recordal of the cancellation of the Existing Charge and the registration of the New Charge, and will submit a copy of the paperwork confirming said actions.

 

IN WITNESS WHEREOF THE PARTIES HAVE EXECUTED THIS

CANCELLATION MEMO AS OF THE DATE FIRST ABOVE WRITTEN:

 

	 	 	 
	 	 	 
	
HOMI INDUSTRIES LTD

	 	BAHRY BUSINESS & FINANCE (1994) LTD
	By: Jacky Ronnel, CEO	 	By: Avraham Bahry, Chairman
	
By: Bella Kivilis, Controller

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00221-of-00352.parquet"}]]